Postmenopausal Osteoporosis: Literature Review
Abstract
Osteoporosis is a chronic condition, similar to heart disease, diabetes, or hypertension. A huge gap exists in the primary prevention of fractures, and studies show that an expected 80% to 90% of adults don't get proper osteoporosis managment even in the secondary prevention setting. Case finding strategies have been created and effective pharmacological mediations are accessible. This review tends to how ideal to utilize the pharmacological choices that anyone could hope to find for postmenopausal osteoporosis to give long lasting fracture protection in patients at high and extremely high risk of fracture. The advantage of osteoporosis treatments far outweighs the uncommon risks.
Keywords
Full Text:
PDFReferences
References
- Nguyen, Nguyen D., et al. "Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks." Osteoporosis International 19 (2008): 1431-1444.
- Cooper, Cyrus. "The crippling consequences of fractures and their impact on quality of life." The American journal of medicine 103.2 (1997): S12-S19.
- Ross, Philip D. "Osteoporosis: frequency, consequences, and risk factors." Archives of internal medicine 156.13 (1996): 1399-1411.
- Torgerson, David J., and Paul Dolan. "Advice given to patients with fractures: drug treatments that reduce fracture rate are underused after vertebral fractures." BMJ: British Medical Journal 318.7199 (1999): 1698.
- Pal, Badal. "Questionnaire survey of advice given to patients with fractures." Bmj 318.7182 (1999): 500-501.
- Epstein, S. "Postmenopausal osteoporosis: fracture consequences and treatment efficacy vary by skeletal site." Aging Clinical and Experimental Research 12 (2000): 330-341.
- Christiansen, C. "Consensus development conference: prophylaxis and treatment of osteoporosis." Am J Med 90 (1991): 107-110.
- Silva, Matthew J., Tony M. Keaveny, and Wilson C. Hayes. "Computed tomography‐based finite element analysis predicts failure loads and fracture patterns for vertebral sections." Journal of Orthopaedic Research 16.3 (1998): 300-308.
- Kanis, John A., and F. A. Pitt. "Epidemiology of osteoporosis." Bone 13 (1992): S7-S15.
- MELTON III, L. JOSEPH, et al. "Epidemiology of vertebral fractures in women." American journal of epidemiology 129.5 (1989): 1000-1011.
- Seeley, Dana G., et al. "Which fractures are associated with low appendicular bone mass in elderly women?" Annals of internal medicine 115.11 (1991): 837-842.
- Sanders, K. M., et al. "The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study." Journal of Bone and Mineral Research 13.8 (1998): 1337-1342.
- Lauritzen, Jes Bruun. "Osteoporotic fractures–epidemiology, fall cascade, risk factors, and prevention." Orthopaedic Issues in Osteoporosis (2003): 171-190.
- Oden, A., et al. "Lifetime risk of hip fractures is underestimated." Osteoporosis international 8 (1998): 599-603.
- Farmer, Mary E., et al. "Race and sex differences in hip fracture incidence." American journal of public health 74.12 (1984): 1374-1380.
- Hagino, H., et al. "The incidence of fractures of the proximal femur and the distal radius in Tottori prefecture, Japan." Archives of Orthopaedic and Trauma Surgery 109 (1989): 43-44.
- Johnel, O., et al. "The apparent incidence of hip fracture in Europe: a study of national register sources." Osteoporosis international 2 (1992): 298-302.
- Gullberg, B., O. Johnell, and J. A. Kanis. "World-wide projections for hip fracture." Osteoporosis international 7 (1997): 407-413.
- Kanis, John A., et al. "Guidelines for diagnosis and management of osteoporosis." Osteoporosis international 7 (1997): 390-406.
- Block, J. E., and H. Stubbs. "Hip fracture-associated mortality reconsidered." Calcified tissue international 61.1 (1997): 84.
- Schürch, M‐A., et al. "A prospective study on socioeconomic aspects of fracture of the proximal femur." Journal of Bone and Mineral Research 11.12 (1996): 1935-1942.
- Johnell, Olof. "The socioeconomic burden of fractures: today and in the 21st century." The American journal of medicine103.2 (1997): S20-S26.
- Jalovaara, Pekka, and Heikki Virkkunen. "Quality of life after primary hemiarthroplasty for femoral neck fracture: 6-year follow-up of 185 patients." Acta Orthopaedica Scandinavica62.3 (1991): 208-217.
- Cummings, Steven R., Dennis M. Black, and Susan M. Rubin. "Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women." Archives of internal medicine 149.11 (1989): 2445-2448.
- Chrischilles, E., T. Shireman, and R. Wallace. "Costs and health effects of osteoporotic fractures." Bone 15.4 (1994): 377-386.
- Phillips, Spencer, et al. "The direct medical costs of osteoporosis for American women aged 45 and older, 1986." Bone 9.5 (1988): 271-279.
- Greendale, Gail A., et al. "Late physical and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study." Journal of the American Geriatrics Society 43.9 (1995): 955-961.
- Center, Jacqueline R., et al. "Mortality after all major types of osteoporotic fracture in men and women: an observational study." The Lancet 353.9156 (1999): 878-882.
- Cooper, Cyrus, et al. "Population-based study of survival after osteoporotic fractures." American journal of epidemiology137.9 (1993): 1001-1005.
- Ross, Philip D. "Clinical consequences of vertebral fractures." The American journal of medicine 103.2 (1997): S30-S43.
- Nevitt, Michael C., et al. "The association of radiographically detected vertebral fractures with back pain and function: a prospective study." Annals of internal medicine 128.10 (1998): 793-800.
- Huang, Chun, Philip D. Ross, and Richard D. Wasnich. "Vertebral fracture and other predictors of physical impairment and health care utilization." Archives of internal medicine156.21 (1996): 2469-2475.
- Epstein, S. "Postmenopausal osteoporosis: fracture consequences and treatment efficacy vary by skeletal site." Aging Clinical and Experimental Research 12 (2000): 330-341.
- Ettinger, Bruce, et al. "Contribution of vertebral deformities to chronic back pain and disability." Journal of Bone and Mineral Research 7.4 (1992): 449-456.
- Frost, H. M. "Personal experience in managing acute compression fractures, their aftermath, and the bone pain syndrome, in osteoporosis." Osteoporosis international 8 (1998): 13-15.
- Cook, Deborah J., et al. "Quality of life issues in women with vertebral fractures due to osteoporosis." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 36.6 (1993): 750-756.
- Cauley, J. A., et al. "Risk of mortality following clinical fractures." JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE. Vol. 8. No. 5. 2 MADISON AVENUE, LARCHMONT, NY 10538 USA: MARY ANN LIEBERT INC PUBL, 1999.
- Huang, Chun, et al. "Contributions of vertebral fractures to stature loss among elderly Japanese‐American women in Hawaii." Journal of Bone and Mineral Research 11.3 (1996): 408-411.
- Leidig‐Bruckner, G., et al. "Clinical grading of spinal osteoporosis: quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis." Journal of Bone and Mineral Research 12.4 (1997): 663-675.
- Gold, D. T. "The clinical impact of vertebral fractures: quality of life in women with osteoporosis." Bone 18.3 (1996): S185-S189.
- Melton, LJ 3rd, et al. "Secular trends in hip fracture incidence and recurrence." Osteoporosis International 20 (2009): 687-694.
- McClung, Michael R., et al. "Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study." The Journal of Clinical Endocrinology & Metabolism 89.10 (2004): 4879-4885.
- Doube, Alan. "Managing osteoporosis in older people with fractures needs to be taken as seriously as coronary artery disease." BMJ 318.7182 (1999): 477-478.
- Skedros, John G., et al. "The orthopedist as clinical densitometrist: Cost-and time-effectiveness." AMERICAN JOURNAL OF ORTHOPEDICS-BELLE MEAD- 36.1 (2007): 15.
- Schott, A. M., et al. "How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study." Osteoporosis international 8 (1998): 247-254.
- Marshall, Deborah, Olof Johnell, and Hans Wedel. "Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures." Bmj 312.7041 (1996): 1254-1259.
- Ross, P. D., et al. "Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women." Osteoporosis International 3 (1993): 120-126.
- Looker, A. C., et al. "Updated data on proximal femur bone mineral levels of US adults." Osteoporosis international 8 (1998): 468-490.
- Landsman, CM Klotzbuecher PD Ross PB, and TA Abbott Suffix III M. Berger. "ArticleTitle Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis." J Bone Miner Res 15 (2000): 721-739.
- Nevitt, M. C., et al. "Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures." Bone 25.5 (1999): 613-619.
- Ross, Philip D., et al. "Pre-existing fractures and bone mass predict vertebral fracture incidence in women." Annals of internal medicine 114.11 (1991): 919-923.
- Faulkner, K. G., et al. "Heel BMD and the NOF criteria predict fractures in both Caucasian and non-Caucasian women." OSTEOPOROSIS INTERNATIONAL. Vol. 11. SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND: SPRINGER-VERLAG LONDON LTD, 2000.
- Geusens, Piet, and Steven Boonen. "Risk assessment for osteoporosis using bone mineral density determination: a belgian perspective." Journal of Clinical Densitometry 1.4 (1998): 355-358.
- Brennan, N. J., and G. A. Caplan. "Attitudes to osteoporosis and hormone replacement therapy among elderly women." Osteoporosis international 9 (1999): 139-143.
- Guyatt, Gordon H. "Evidence-based management of patients with osteoporosis." Journal of Clinical Densitometry 1.4 (1998): 395-402.
- Seeman, Ego. "Osteoporosis: trials and tribulations." The American journal of medicine 103.2 (1997): S74-S89.
- Meunier, P. J. "Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials." International Journal of Clinical Practice 53.2 (1999): 122-129.
- Hochberg, Marc C., et al. "Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 42.6 (1999): 1246-1254.
- Riggs, B. Lawrence, et al. "Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis." New England journal of medicine 322.12 (1990): 802-809.
- Black, Dennis M., et al. "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures." The Lancet 348.9041 (1996): 1535-1541.
- Chapuy, Marie C., et al. "Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women." BMJ: British Medical Journal 308.6936 (1994): 1081.
- Ettinger, Bruce, et al. "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial." Jama 282.7 (1999): 637-645.
- Harris, Steven T., et al. "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial." Jama 282.14 (1999): 1344-1352.
- Reginster, J-Y., et al. "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis." Osteoporosis international 11 (2000): 83-91.
- Hillner, Bruce E., et al. "American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer." Journal of Clinical Oncology 21.21 (2003): 4042-4057.
- Miller, P. "Risedronate reduces hip fractures in patients with low femoral neck bone mineral density." Arthritis Rheum 42.9 (1999): S287-S295.
- Hochberg, Marc. "Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents." Drugs & aging 17 (2000): 317-330.
- Cummings, Steven R., et al. "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial." Jama280.24 (1998): 2077-2082.
- Liberman, U. A., et al. "II, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis." N Engl J Med 333.22: 1437-1443.
- Karpf, David B., et al. "Prevention of nonvertebral fractures by alendronate: a meta-analysis." JaMa 277.14 (1997): 1159-1164.
- Ensrud, K., et al. "Prevalent vertebral fractures predict hospitalization and mortality in older women: The fracture intervention trial (FIT)." ARTHRITIS AND RHEUMATISM. Vol. 41. No. 9. 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA: LIPPINCOTT WILLIAMS & WILKINS, 1998.
- Schnitzer, T. "Bone HG. Crepaldi G. Adami S. McClung M. Kiel D. et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group." Aging (Milano) 12 (2000): 1-12.
- Lips, Paul, et al. "Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial." Annals of Internal Medicine 124.4 (1996): 400-406.
- Dawson-Hughes, Bess, et al. "Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older." New England Journal of Medicine 337.10 (1997): 670-676.
- Riggs, B. Lawrence, et al. "Long‐term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women." Journal of Bone and Mineral Research 13.2 (1998): 168-174.
- Cosman, Felicia, Steven Cummings, and Robert Lindsay. "Guest Editorial: How Long Should Patients with Osteoporosis Be Treated with Bisphosphonates?" Journal of Women's Health & Gender-Based Medicine 9.2 (2000): 81-84.
- Tonino, Richard P., et al. "Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women." The Journal of Clinical Endocrinology & Metabolism 85.9 (2000): 3109-3115.
- Mashiba, Tasuku, et al. "Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib." Journal of Bone and Mineral Research 15.4 (2000): 613-620.
- Balena, R., et al. "The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates." The Journal of clinical investigation 92.6 (1993): 2577-2586.
- Weinstein, Robert S. "Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity." Bone 46.3 (2010): 564-570.
- Reid, Ian R., et al. "Intravenous zoledronic acid in postmenopausal women with low bone mineral density." New England Journal of Medicine 346.9 (2002): 653-661.
- Neer, Robert M., et al. "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis." New England journal of medicine 344.19 (2001): 1434-1441.
- Finkelstein, Joel S., et al. "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis." New England Journal of Medicine 349.13 (2003): 1216-1226.
- Finkelstein, Joel S., et al. "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis." New England Journal of Medicine 349.13 (2003): 1216-1226.
- Orwoll, ESWH SCHEELES, et al. "The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis." Journal of bone and mineral research 18.1 (2003): 9-17.
- Abramowicz, Mark. "Teriparatide (Forteo) for osteoporosis." Medical Letter on Drugs and Therapeutics 45.1149 (2003): 9-9.
- Rossouw, Jacques E., et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial." Jama 288.3 (2002): 321-333.
- Grady, Deborah, et al. "Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)." Jama 288.1 (2002): 49-57.
- Grady, Deborah, et al. "Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)." Jama 288.1 (2002): 49-57.
- Lindsay, Robert, et al. "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women." Jama 287.20 (2002): 2668-2676.
- Recker, Robert R., et al. "The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial." Annals of internal medicine 130.11 (1999): 897-904.
- Ferrari, Serge, et al. "Relationship between bone mineral density T‐score and nonvertebral fracture risk over 10 years of denosumab treatment." Journal of Bone and Mineral Research 34.6 (2019): 1033-1040.
- Cummings, Steven R., et al. "Goal‐directed treatment for osteoporosis: a progress report from the ASBMR‐NOF working group on goal‐directed treatment for osteoporosis." Journal of Bone and Mineral Research 32.1 (2017): 3-10.
- Michael Lewiecki, E. "Osteoporosis: treat-to-target." Current Osteoporosis Reports 15 (2017): 103-109.
- Bouxsein, Mary L., et al. "Change in bone density and reduction in fracture risk: a meta‐regression of published trials." Journal of Bone and Mineral Research 34.4 (2019): 632-642.
- Dennison, Elaine M., et al. "Fracture risk following intermission of osteoporosis therapy." Osteoporosis International 30 (2019): 1733-1743.
- Eastell, Richard, et al. "Effect of stopping risedronate after long-term treatment on bone turnover." The Journal of Clinical Endocrinology & Metabolism 96.11 (2011): 3367-3373.
- Black, Dennis M., et al. "Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial." Jama 296.24 (2006): 2927-2938.
- Brown, Jacques P., et al. "Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays." Canadian Family Physician 60.4 (2014): 324-333.
- Black, Dennis M., et al. "The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON‐Pivotal Fracture Trial (PFT)." Journal of bone and mineral research 27.2 (2012): 243-254.
- Black, Dennis M., et al. "The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON‐Pivotal Fracture Trial (PFT)." Journal of Bone and Mineral Research 30.5 (2015): 934-944.
- Lyles, Kenneth W., et al. "Zoledronic acid and clinical fractures and mortality after hip fracture." New England Journal of Medicine 357.18 (2007): 1799-1809.
- Adler, Robert A., et al. "Managing osteoporosis in patients on long‐term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research." Journal of Bone and Mineral Research 31.1 (2016): 16-35.
- Miller, P. D., et al. "Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates." Osteoporosis International 31 (2020): 181-191.
- Eastell, Richard, et al. "Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline." The Journal of Clinical Endocrinology & Metabolism 104.5 (2019): 1595-1622.
- Bone, Henry G., et al. "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass." The Journal of Clinical Endocrinology & Metabolism 96.4 (2011): 972-980.
- Freemantle, N., et al. "Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women." Osteoporosis International 23 (2012): 317-326.
- Sølling, Anne Sophie, Torben Harsløf, and Bente Langdahl. "Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial." Journal of Bone and Mineral Research 35.10 (2020): 1858-1870.
- Bone, Henry G., et al. "10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension." The lancet Diabetes & endocrinology 5.7 (2017): 513-523.
- Cummings, Steven R., et al. "Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo‐controlled FREEDOM trial and its extension." Journal of Bone and Mineral Research 33.2 (2018): 190-198.
- Ferrari, Serge, et al. "Further nonvertebral fracture reduction beyond 3 years for up to 10 years of denosumab treatment." The Journal of Clinical Endocrinology & Metabolism 104.8 (2019): 3450-3461.
- Bates, David W., Dennis M. Black, and Steven R. Cummings. "Clinical use of bone densitometry: clinical applications." Jama288.15 (2002): 1898-1900.
DOI: http://dx.doi.org/10.52155/ijpsat.v37.1.5052
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Maged Naser
This work is licensed under a Creative Commons Attribution 4.0 International License.